GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

Doximity

DexCom

Hims & Hers Health

23andMe

Oscar Health

Progyny

Teladoc

Tempus AI Inc

Waystar Holding Corp

It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health companies, around two-thirds have lost value this year, while the Nasdaq is up 32%.

Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that executives from the Company will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time). A live webcast will be available on the Company's Investor Relations website, https://investors.

GoodRx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today revealed startling healthcare disparities in its new report, “Endocrinologist Deserts: A Critical Healthcare Gap for Millions in the U.S.” With nearly 70% of U.S. counties lacking an endocrinologist, the report paints a stark picture of the barriers millions of Americans face in managing life-threatening conditions like diabetes. The findings come at a critical time as the.

GoodRx Report Shows Millions at Risk as Endocrinologist Shortages Hit Nearly 70% of U.S. Counties

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (NASDAQ: GDRX), the leading prescription savings platform in the U.S., today announced that Wendy Barnes has been appointed as President and Chief Executive Officer, effective January 1, 2025. Wendy brings more than 30 years of leadership experience across the pharmacy and medical benefit industry to her new role. Wendy will join GoodRx following her role as CEO of RxBenefits, where she led the company in providing pharmacy benefit su.

GoodRx Appoints Healthcare Industry Veteran, Wendy Barnes, as New Chief Executive Officer

Prescription fills for blockbuster weight loss medications in the U.S. more than doubled in 2024, even with limited insurance coverage and high out-of-pocket costs for the treatments. That's according to new data from drug savings company GoodRx, which examined fill trends and spending patterns for weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today released a new Weight Loss Medications Tracker that provides an inside look at fill trends and spending patterns for weight loss medications across the U.S. The company found that limited insurance coverage and high out-of-pocket costs aren't slowing down interest in popular drugs used for weight loss such as Mounjaro, Ozempic, Wegovy, and Zepbound. In fact, some of these p.

GoodRx Reveals Americans Overspent on Weight Loss Medications by $200 Million This Year, Fills Still Surged

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Helps, a 501(c)(3) nonprofit organization seeking to address health inequities across the country, has selected its 2024 Students for Healthcare Equity Scholarship recipients. The scholarship program was created to encourage culturally responsive healthcare by providing financial assistance to healthcare students from underrepresented groups. To date, GoodRx Helps has granted $325,000 in scholarships to students advocating for equitable access to he.

GoodRx Helps Announces Recipients of 2024 Students for Healthcare Equity Scholarship

NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of GoodRx Holdings, Inc. (NASDAQ: GDRX)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, GoodRx insiders caused the company to misrepresent or fail to disclose that (1) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx discounts, Kroger was responsible for nearly 25% of GoodRx's total prescription transactions revenue (the Company's primary revenue stream); and (2) Kroger could unilaterally cease accepting GoodRx discounts, cutting off some or all of GoodRx's revenues for purchases at Kroger's pharmacies; and (3) as a result, representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Kuehn Law Encourages Investors of GoodRx Holdings, Inc. to Contact Law Firm

Harrow Health Inc

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., providing patients with discounts on select Harrow products. This.

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of long-term stockholders following a class action complaint that was filed against GoodRx on April 22, 2024 with a Class Period from September 23, 2020, to November 8, 2022. Our investigation concerns whether the board of directors of GoodRx have breached their fiduciary duties to the company.

GOODRX ALERT: Bragar Eagel & Squire, P.C. is Investigating GoodRx Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

The company is growing key fundamentals. However, the improvements weren't enough to impress the market.

Why GoodRx Holdings Stock Was Sinking This Week

GoodRx Holdings, Inc. (GDRX) Q3 2024 Earnings Call Transcript

While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GoodRx (GDRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.06 per share a year ago.

GoodRx Holdings, Inc. (GDRX) Misses Q3 Earnings and Revenue Estimates

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $195.3 million Net income of $4.0 million; Net income margin of 2.0% Adjusted Net Income1 of $31.9 million; Adjusted Net Income Margin1 of 16.4% Adjusted EBITDA1 of $65.0 million; Adjusted.

GoodRx Reports Third Quarter 2024 Results

Beyond analysts' top -and-bottom-line estimates for GoodRx (GDRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.

GoodRx (GDRX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

CVS Health

Smaller pharmacies are accusing GoodRx and CVS of colluding to suppress generic prescription drug reimbursements. As Reuters reported Tuesday (Nov. 5), drug coupon aggregator GoodRx and a pair of pharmacy benefit managers (PBMs) — CVS's Caremark unit and Express Scripts — have all been named in at least three lawsuits by independent pharmacies.

GoodRx and CVS Sued for Suppressing Pharmacy Reimbursement

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that executives from the Company will participate in a fireside chat at each of the following investor conferences: UBS 2024 Global Healthcare Conference in Rancho Palos Verdes, CA, on Tuesday, November 12, 2024 at 2 p.m. Eastern Time (11 a.m. Pacific Time) Citi 2024 Global Healthcare Conference in Miami, FL, on Thursday,.

GoodRx to Participate in Upcoming Investor Conferences

SANTA MONICA, Calif.--(BUSINESS WIRE)--Today, GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced the rollout of its new e-commerce solution, with Opill® as its launch partner. This new seamless direct-to-consumer shopping experience allows consumers to order eligible health products and medications on the GoodRx platform and have them shipped directly to their door. Not only does this mark GoodRx's entry into the over-the-counter (OTC) market, but it offers.

GoodRx Unveils New E-commerce Platform, Launches with Opill®

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today that QSYMIA® (phentermine and topiramate extended-release capsules CIV) is available for a low cash price in more than 70,000 retail pharmacy locations nationwide exclusively via GoodRx. This initiative not only propels GoodRx's momentum in weight loss solutions, but also broadens its portfolio in offering significant savings on brand-name medications, making obes.

GoodRx Announces Exclusive Low Cash Price for QSYMIA®, the Leading Branded Once-Daily Oral Weight Management Medication for Adults

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced the election of Ronald E. Bruehlman to its Board of Directors, effective November 8, 2024. Mr. Bruehlman brings to GoodRx 39 years of finance experience in the healthcare services, industrial and petroleum industries. He currently serves as Chief Financial Officer of IQVIA, a global provider of advanced.

Ronald E. Bruehlman Joins GoodRx Board of Directors

SANTA MONICA, Calif.--(BUSINESS WIRE)--Today, GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced the availability of new affordability programs for menopause hormone therapies by Pfizer. Through the reach and scale of the GoodRx platform, these programs are broadening access and affordability of crucial medications for women. New research from GoodRx shows menopause medications have increased in list price by 58% since 2014. And according to a recent study,.

GoodRx Announces New Affordability Programs for Menopause Hormone Therapies

SAN FRANCISCO--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), the leading prescription savings platform in the U.S., today announced consumers will soon be able to use Affirm to pay over time for select medications at participating retail pharmacies. This adds a convenient way for consumers to pay for their medications directly on the GoodRx platform. GoodRx is launching this program with its partner pharmacies, including Hy-Vee, a grocery retailer with a network of more than 275 retail pharmacies. To.

GoodRx Partnering with Retail Pharmacies to Deliver Pay-Over-Time Option Directly to Consumers

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 7, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference.

GoodRx Announces Date for Third Quarter 2024 Earnings Release and Conference Call

Today, we are circling back on GoodRx Holdings, which offers a platform for comparing prescription drug prices. The company also enables their customers to benefit from negotiated prices through GoodRx codes that are used to save money on prescriptions. The stock has a bit of a rocky ride since forward guidance disappointed following second-quarter results.

News for GoodRx Holdings Stock (GDRX)